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A B S T R A C T
In the European Union, traditional herbal medicines that are regarded as “acceptably 
safe, albeit not having a recognized level of efficacy” fit into a special category of drugs 
(“traditional herbal medicine products”) for which requirements of non-clinical and 
clinical studies are less rigorous. A regulation proposal published by the Brazilian National 
Health Surveillance (Anvisa) defines a similar drug category (“traditional phytotherapeutic 
products”) for registration purposes. Regarding herbal medicines, both agencies seem to 
be lenient regarding proof of efficacy, and consider long-standing folk use as evidence of 
safety and a waiver of a thorough toxicological evaluation. Nonetheless, several herbal 
products and constituents with a long history of folk usage are suspected carcinogenic 
and/or hepatotoxic. Herbal products have also been shown to inhibit and/or induce 
drug-metabolizing enzymes. Since herbal medicines are often used in conjunction 
with conventional drugs, kinetic and clinical interactions are a cause for concern. A 
demonstration of the safety of herbal medicines for registration purposes should include 
at least in vitro and in vivo genotoxicity assays, long-term rodent carcinogenicity tests (for 
drugs intended to be continuously used for > 3 months or intermittently for > 6 months), 
reproductive and developmental toxicity studies (for drugs used by women of childbearing 
age), and investigation of the effects on drug-metabolizing enzymes.
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved. 
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Introduction
Traditional or folk medicine comprises practices, approaches, 
knowledge and beliefs not based on scientific evidence that are 
applied to treat, diagnose and prevent illness within a society. 
It is defined by a culture’s knowledge and values and thus is 
context-specific, as are social constructions and negotiations of 
risk. When modern societies adopt such long-standing health 
practices outside of their traditional context, these practices 
become “complementary, non-conventional or alternative 
medicine” (Crellin, 2001).
The extent to which the traditional use of an herb 
ensures that a corresponding herbal drug is safe, however, 
is a debachart matter. A new draft regulation published by 
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the Brazilian National Health Surveillance Agency (Anvisa) 
brought this controversial topic to the center stage. The 
proposed regulation, which has recently undergone a public 
consultation for reviews and comments, defines two categories 
of herbal drugs for registration: “phytotherapeutic medicines” 
and “traditional phytotherapeutic products” (TPTP) (Anvisa, 
2013). A product fits into the latter category if a long-standing 
(traditional) use is identified that has not been proven unsafe 
and is recognized in the literature or demonstrated by ethno-
pharmacological and/or ethno-botanical studies. Once the 
traditional use is recognized, safety and efficacy data from 
pre-clinical and/or clinical studies are no longer essential 
requirements to obtain approval for commercialization. 
The proposed new rules for herbal medicine registration 
in Brazil are, to some extent, similar to the regulation 
released by the European Parliament in 2004. According to 
EC Directive 2004/24, herbal medicines with traditional use 
that are acceptably safe, albeit not having a recognized level 
of efficacy, can be classified as “traditional herbal medicines 
products” (THMP), as detailed by Calapai (2008), Quintus and 
Schweim (2012) and Silano et al. (2004). In order for a medicinal 
product,or its corresponding products (i.e., products having 
the same active ingredients, the same or similar intended 
purpose, equivalent strength and posology and the same or 
similar route of administration), to be classified as THMP, 
it must have been in medicinal use for a period of at least 
30 years, of which more than 15 years must relate to the 
European Union. Herbal drugs in the THMP category undergo 
a simplified registration procedure. Aspiring herbal products 
are required to demonstrate the traditional use of the herb, 
but this requirement is lifted if the product complies with the 
European positive list established by the Committee on Herbal 
Medicinal Products (HPMC) (Knöss and Chinou, 2012). Herbal 
monographs prepared by HPMC are not binding, and member 
state agencies may not agree with every single aspect of the 
monograph. For instance, applicants that refer to a HPMC 
monograph may be required to provide additional points on 
safety (e.g., on genotoxicity). 
In summary, both the European Medicines Agency (EMA) and 
the Brazilian National Health Surveillance Agency (ANVISA) 
recognize a special class of phytopharmaceuticals and take 
tradition into account for pre-marketing demonstrations 
of safety and efficacy, thereby opening a wider door for the 
registration of manufactured herbal products as medicines.
Medicinal herb products: drugs or food 
supplements? 
In contrast to European and Brazilian agencies, the United 
States Food and Drug Administration (US FDA) makes no 
distinction between herbal and conventional medicines 
regarding the requirements for pre-marketing demonstration 
of safety and efficacy (Wu et al., 2008). Owing to this fact, 
herbal products with presumed beneficial effects generally 
do not meet the criteria for approval as medicines, and are 
commercialized in the USA as food supplements. 
The notion that herbal drugs require less rigorous and 
comprehensive safety and efficacy evaluation is questionable. 
There is no scientific rationale to assume that plants, their 
parts and/or derived products, including those of long-standing 
popular use, are intrinsically safe and/or beneficial; or that, 
compared to conventional medicines, they would require fewer 
and simpler pre-clinical and/or clinical studies. For the sake of 
coherence in drug regulations, all medicines, regardless of their 
origin and development, should meet equally rigorous safety 
and efficacy standards for marketing authorization.
So far, the strongest argument against the application of 
the same rule for herbal and conventional medicines has been 
that insufficiently tested, or even untested, herbal medicinal 
products have not been removed from the market in the USA. 
As a matter of fact, these products continue to be widely sold 
and consumed as herbal and dietary supplements (HDS), 
a category of consumer products more loosely regulated by 
the US FDA. A statement of comprehensive and rigorous pre-
marketing safety and drug effectiveness is not an essential 
requirement for HDS. The US Dietary Supplement and Health 
Education Act of 1994, and the Final Rule for Current Good 
Manufacturing Practices for Dietary Supplements of 2007, 
demand that HDS manufacturers define dietary ingredients as 
vitamins, minerals, herbs, and amino acids, provide standards 
in identification and purity, and ensure that claims made 
regarding their products are accurate and not misleading. 
Despite legal restrictions on placing alleged therapeutic 
properties on the product label, HDS are used in conjunction 
with conventional medicines or on their own to treat a variety 
of morbid conditions. Based on this, supporters of keeping a 
separate category of phytotherapeutics for regulation purposes 
argue that this special group of medicines, compared to 
dietary supplements, undergo a more thorough evaluation of 
safety and at least some assessment of efficacy, and are also 
under more stringent rules regarding quality assurance and 
manufacturer adherence to GMP.
Drug safety and efficacy 
In reference to medications, safety is the likelihood of not 
causing harm under the proposed conditions of use, while 
efficacy is the capacity to induce a clinical benefit. Both safety 
and efficacy depend on the drug’s therapeutic indication; in 
principle, a substance has no clinical usefulness if it is “safe” 
but lacks efficacy or if it is active on a relevant therapeutic 
target but its use is unsafe. Although these are recognized as 
equally essential attributes of any medicine, safety has taken 
precedence over proof of efficacy in drug regulation history. 
In the US, for instance, the Federal Food Drug and Cosmetic 
Act of 1938 required that safety of new drugs had to be proven 
by pre-marketing testing, whereas similar requirements to 
demonstrate drug efficacy were introduced only 25 years later 
by the Kefauver-Harris Amendments of 1962.
The idea that safety should come first in therapeutic 
interventions is conveyed by the famous Latin expression 
“primum non nocere” (“first, not do harm”), the origin of which 
is uncertain (Smith, 2005). Similarly, the classical version 
of the Hippocratic Oath that physicians take upon entering 
medical practice contains a promise that expresses a similar 
idea (doctors are required to “keep [patients] from harm”). 
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Although the “non-maleficence” maxim has become a central 
axiom of therapeutics, ethically, it cannot be dissociated from 
the beneficence principle. If a clinical benefit superior to that 
offered by a placebo is attainable by using currently available 
therapeutic interventions, then not to prescribe the most 
effective therapeutic option available has a prejudicial impact 
on the patient’s health.
According to the prevailing concept of evidence-based 
medicine (EBM; “…use of current best evidence in making decisions 
about the care of individual patients”) (Sackett et al., 1996), 
controlled and randomized clinical trials, and an unbiased 
systematic review with and without a meta-analysis, rank 
first in the hierarchy of sources of evidence for the safety and 
efficacy of therapeutic interventions. Clinical efficacy cannot 
be presumed on the basis of pharmacological actions described 
in animal and/or in vitro experiments, nor on physicians’/
experts’ opinions only. It has to be demonstrated by adequately 
designed and conducted phase III studies, or exceptionally by 
phase II trials. 
Randomized clinical trials controlled with placebos reveal 
a number of potential adverse effects associated with drug 
treatment. If patients allocated to the control group receive 
a reference medicine instead of a placebo, the incidences 
of putative adverse effects are compared between the 
reference and the test drug groups. At any rate, controlled 
and randomized clinical trials generally provide the best 
evidence of safety obtainable before marketing. Some aspects 
of drug safety, however, are not fully addressed by clinical 
trial protocols; thus, a comprehensive evaluation of safety also 
requires non-clinical assays, such as long-term carcinogenicity 
tests (cancer inducing potential), reproductive and 
developmental toxicity studies (teratogenic potential) among 
others. It should be noted that some rare but severe adverse 
events arising from interactions with drugs and nutrients, or 
that occur only in subgroups of patients not represented in 
the randomized study groups, are likely to be detected only 
under the actual event of use by a much larger population. 
Therefore, post-marketing pharmacovigilance (PV) is essential 
for a thorough evaluation of drug safety. The same holds true 
for the assessment of drug effectiveness or efficacy under the 
real (post-marketing) conditions of use (Box 1). 
Suspicions of ineffectiveness, however, do not seem to have 
the same weight as safety concerns when reconsideration of 
a drug marketing authorization is on the chart. While the 
uncovering of unexpected severe adverse reactions by PV 
often results in the withdrawal of a drug from the market, the 
suspicion of reduced effectiveness or even ineffectiveness has 
seldom prompted regulators to take such drastic action.
Examples of medicinal products that, despite regulation 
by Anvisa, are exempt from scientific-based demonstration 
of efficacy are the homeopathic drugs (so-called “dynamized” 
medications). A systematic review of placebo-controlled trials 
of homeopathy brought about findings that were compatible 
with the notion that the clinical effects of homoeopathic 
medications are indeed placebo effects (Lind et al., 2001; Shang 
et al., 2005). Owing to the extreme dilution of such “dynamized” 
medications, they are presumed safe, thus, no pre-clinical 
studies are required either. The Anvisa requirements to register 
a homeopathy medicine are manufacturing in compliance 
with the methods of preparation and control described by the 
current edition of the Brazilian Homeopathic Pharmacopeia 
(2011) or other homeopathic pharmacopeias, and “proven 
therapeutic action” is reported in officially recognized 
homeopathy compendia. 
The leniency of regulators and physicians regarding the 
demonstration of the efficacy of herbal drugs seems to be 
rooted in the general belief that herbal products are markedly 
safe. Because of this, even when phytotherapeutic drugs have 
a reduced efficacy, or are not clinically superior to a placebo, 
many regulators and physicians believe that they might 
exhibit favorable risk to benefit ratios. If an herbal medicine’s 
clinical superiority over a placebo remains unproven, however, 
even low risks of slight to mild adverse health effects seem 
unaccepchart (i.e., lack of a clinical benefit implies that risk to 
benefit ratios are unfavorable, even if risks are low).
Tradition and safety of herbal medicines 
Many supporters of herbal medicines argue that products with 
a long history of popular use are generally safe when used 
properly at common therapeutic doses (Fong, 2002). A crucial 
question underlying this statement is the extent to which the 
absence of evidence of toxicity could be taken as evidence of 
the absence of toxicity or safety of herbal medicines. Whether 
the absence of records of adverse effects is an indication of lack 
of toxicity depends on the type of toxic effect and the likelihood 
of observing such an adverse outcome under the conditions 
prevailing in the traditional usage. Acute symptoms and short-
term toxic effects, such as gastro-intestinal disturbances 
and dermatological effects, are likely to be recognized and 
associated to herbal medicine. Therefore, the absence of 
such observations provides some evidence of safety in these 
particular endpoints. Long-term adverse outcomes, such as 
cancer, liver and kidney damage, reproductive dysfunctions, 
birth defects and several morbidities that are more difficult to 
detect, however, are unlikely to be associated with the popular 
use of a medicine, unless an adequately designed epidemiology 
study (preferably, a prospective cohort study) is undertaken. 
Thus, the absence of evidence of these adverse effects within 
the context of traditional usage of herbal medicines is not 
evidence of the absence of potential to cause them. As far as 
drugs are concerned, safety is assumed only when the null 
hypothesis (absence of toxicity) has not been disproved after 
being challenged by properly designed and comprehensive set 
of pre-clinical and clinical studies, that had enough statistical 
power to reject it if it were false. 
Carcinogenic effects of traditional herbal 
medicines 
During R&D of conventional drugs, carcinogenic potential is 
assessed through a battery of in vitro and in vivo short-term 
genotoxicity tests, and long-term rodent carcinogenicity 
assays. Carcinogenicity tests in rats and mice are the longest 
and most costly non-clinical safety studies commonly required 
for a new drug marketing approval. A waiver of long-term 
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carcinogenicity studies for marketing approval can be obtained 
if results of short-term genotoxicity tests are negative and the 
drug is intended to be used continuously for less than three 
months, or intermittently for less than six months. Long-term 
carcinogenicity studies have seldom been performed with 
herbal products, and the data of their genotoxic potential are 
scant as well. Owing to their limited duration, clinical trials 
do not shed light on the carcinogenic potential of drugs. In 
principle, evidence on the carcinogenicity of traditional 
herbal medicines could be obtained from observational 
epidemiological studies. Nonetheless, epidemiological studies 
have rarely been undertaken to address this question. 
As shown in Chart 1, a number of traditionally used 
medicinal plants and their constituents are suspected of being 
human and/or rodent carcinogens. Because a vast majority of 
herbal medicines and their constituents have not undergone 
any screening for carcinogenicity, it is fair to assume that plants 
and substances listed in Chart 1 are just the tip of the iceberg. 
At any rate, evidence that plants with hundreds of years of folk 
usage may induce cancer illustrates that proven traditional use 
on its own does not ensure that an herbal medicine is safe. 
Liver toxicity associated with herbal medicines
Severity of drug-induced liver toxicity (DILI) ranges from 
mild dysfunction leading to raised serum levels of alanine 
aminotransferase (ALT) unaccompanied by increases in 
bilirubin levels and clinical symptoms reversible upon 
treatment discontinuation, to jaundice and overt hepatic failure 
that could culminate in liver transplantation or death. DILI can 
be broadly divided into two types: liver toxicity that depends 
on the dose and can be predicted by pre-clinical and clinical 
studies; and an idiosyncratic DILI that is a rare, but severe 
form of liver damage that occurs only in susceptible individuals 
(presumably involving immuno-allergic mechanisms) and 
cannot be predicted by pre-marketing safety studies. 
Similar to conventional drugs, herbal medicines are capable 
of causing both predicchart and idiosyncratic DILI. Some herbal 
drugs that have been associated with severe hepatotoxic events 
through traditional use are listed in Chart 2. It should be noted 
that the degree of evidence for establishing a causal link between 
intake of a medicinal herb and liver impairment is variable, as 
it is for conventional drugs. In addition to the difficulties and 
limitations of pharmacovigilance, the vigilance related to herbal 
products faces additional problems, such as: self-medication, 
products that contain a diverse number of different plants, 
use in combination with classical pharmaceutical agents, the 
widespread belief that natural products are intrinsically safe so 
that patients often forget to disclose this information to their 
physicians, and poor quality issues, including misidentification 
of the plants, selection of the wrong part of the plant, 
adulteration, mislabeling, inadequate storage conditions, and 
contamination by fungi, pesticides, metals and other potential 
toxins (Larrey and Faure, 2011; Shaw et al., 2012).
The fact that several hepatotoxic plants and their 
constituents have a long-standing use in folk medicine is also 
consistent with the notion that traditional use on its own does 
not guarantee the safety of a phytopharmaceutical.
Kinetic interactions of herbal medicines with 
conventional medicines 
Herbal medicines are often used concomitantly with 
conventional drugs, making potential pharmacokinetic 
interactions a cause for concern. Herbal drug co-administration 
with medicines of narrow therapeutic indices (e.g., digoxin, 
warfarin) raises even deeper safety concerns. Common 
herbal medicines known to interact with conventional drugs 
include St. John’s wort (Hypericum perforatum L.), ginkgo 
(Ginkgo biloba L.), ginger (Zingiber officinale Rosc.), ginseng 
(Panax ginseng C.A. Meyer) and garlic (Allium sativum L.) 
(Chart 3). St. John’s wort, an herbal antidepressant, is possibly 
the most notorious example. It is a potent inhibitor of CYP3A4, 
and when co-administered with drugs metabolized by this 
enzyme, it decreases their clearance and increases their plasma 
concentrations (AUC). Because St. John’s wort also induces the 
expression of CYP3A4 and the transmembrane transporter 
protein PgP (P-glycoprotein) in the liver and intestines, 
previous and repeated administrations have opposite effects; 
enhancement of clearance and decrease in AUC. The kinetic 
and clinical effects of a number of drugs that are substrates for 
CYP3A4 are altered by St. John’s wort, and these drugs include 
cyclosporine, midazolam, oxycodone, methadone, imatinib, 
finasteride, bupropion, tracolimus, digoxin, atorvastin, and 
verapamil, among others. 
As shown in Chart 3, herbal products and their constituents 
can alter the activity and/or expression of drug-metabolizing 
enzymes and transmembrane transporters, and by doing so, 
they can modify drug elimination, metabolic activation (i.e., 
conversion of a precursor into its active metabolite), pre-
systemic clearance, bioavailability, and kinetic parameters 
such as AUC, Cmax and Tmax. All these effects may eventually 
lead to changes in toxicity and/or clinical efficacy of 
conventional drugs. Therefore, knowledge of the potential 
of herbal medicines to inhibit (when co-administered) and/
or induce the expression (after previous and/or repeated 
administration) of key drug-metabolizing enzymes (e.g., 
CYP3A4, 2D6, 2C9, 2C19, 2A6) is of the utmost importance for 
safety when used in conjunction with conventional drugs. 
Concluding remarks 
Within the prevailing concept of evidence-based medicine, 
traditional use and expert opinion are at the lowest levels in 
the hierarchy of evidence for the safety and efficacy of drugs. 
The highest evidence for safety and efficacy is that arising from 
randomized clinical trials and an unbiased systematic review 
with or without a meta-analysis. 
The lack of controlled and randomized clinical trials of 
herbal medicines with a long history of use in Brazil and/
or other countries is the rule rather than the exception. In 
the last decade, several clinical studies (including a few 
controlled and randomized trials of traditional Chinese herbal 
medicines) were undertaken, and others are ongoing (Fu et al., 
2013; Hao et al., 2013; Li et al., 2012; Liu et al., 2013). In addition 
to the shortcomings in clinical trial design, execution and data 
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Plant species Constituent Traditional use
Evidence
ReferenceHumans or 
animals
Findings
Aristolochia 
sp.
Aristolochic  
acid (AA)
Chinese traditional 
medicine; arthritis, 
rheumatism, hepatitis, 
other indications.
Human
Nephrotoxicity, upper tract urothelial 
carcinoma; meta-analysis: OR = 5.97 
(95% CI, 2.78-12.84) for AA-related 
cancers; TP53 mutations.
Chen et al., 2013;  
Hollstein et al., 2013;  
Wu and Wang, 2013.
Thuja sp., 
Artemisia 
sp., Salvia 
officinalis L.
D-E-thujone 
(essential oils)
Traditional medicine, 
flavoring food additives, 
absinthe (liqueur).
Rodents
Inhibitor of GABA-A receptor, seizures. 
Preputial gland and adrenal gland 
tumors in male rats (no treatment-
related tumors in female rats and 
mice).
Halicioglu et al., 2011;  
NTP, 2011a,  
Pelkonen et al., 2013. 
Mentha × 
piperita L., M. 
longifolia (L.) 
Huds.,  
Nepeta  
cataria L. 
Peppermint  
and  
pennyroyal  
oils; pulegone
Traditional medicine, 
flavoring food additives.
Rodents
Hyaline glomerulopathy (male, female, 
mice, rats); Urinary bladder neoplasms 
(female rats), hepatocellular neoplasms 
(mice), osteoma/osteosarcoma (female 
mice), no tumors in male rats.
NTP, 2011b
Sassafras 
albidum 
(Nutt.) Nees, 
Areca  
catechu L.,  
Piper betle L. 
Sassafras  
oil; safrole
Traditional medicine, 
Native Americans and  
the British, betel quid 
chewing in Asia.
Human
Rodents
Oral squamous carcinomas (humans), 
hepatocellular carcinomas; DNA-
adduct formation and potent 
 rodent carcinogen.
Amarasinghe et al., 2010; 
Chen et al., 1999;  
Hsieh et al., 2001; Kapadia  
et al., 1978; Liu et al., 2000.
Pteridium 
sp. (braken), 
ferns and 
lycopods
Sesquiterpenois 
and analogues; 
ptaquiloside
Food (East Asia and 
American Indians), food  
and traditional medicine  
(New Zealand, 
the Maoris).
Human
Rodents
Cattle
in vitro
Stomach and upper alimentary 
tract cancers, urinary bladder 
cancer, neoplasia of several tissues 
(rodents), thyamine deficiency, 
acute haemorrhage associated with 
myeloid aplasia, blindness and 
retinal degeneration, genotoxicity, 
teratogenicity.
Alonso-Amelot and 
Avendaño, 2002; Potter and 
Baird, 2000; Shahin et al., 
1999; Tomšík, 2013.
Symphytum 
officinale L. 
(comfrey)
Pyrrolizidine 
alkaloids
Traditional medicine, 
Africa, China, Ayurveda, 
and others.
Human
Rodents
Hepatotoxicity, hepatic venous 
occlusive disease, liver cancer, 
genotoxicity, DNA adducts.
Chen et al., 2010; Mei et al., 
2011; Roeder, 2000; Roeder 
and Wiedenfeld, 2011; 2013; 
Steenkamp et al., 2000.
Euphorbia 
tirucalli L.
Phorbol esters
Traditional medicine, 
Africa.
Human
Rodents
Burkitt’s lymphoma after co-exposure 
E. tirucalli + Epstein Barr virus, known 
tumor promoting agent in rodents.
Aya et al., 1991;  
Imai et al., 1994.
Gingko  
biloba L.
Leaf extract
Chinese traditional 
medicine, widespread use 
worldwide.
Human
Rodents
Dose-related increase in liver 
tumors including hepatocellular 
carcinoma (B6C3F1 mice). Evidence of 
carcinogenic potential in the thyroid 
gland (rats, mice); mutagenic (S. 
typhimurium TA98, TA100, E. coli WPS 
uvrA/pkM 101, with and without S9).
Hoenerhoff et al.,  
2013;  
NTP, 2013.
Rubia 
tinctorum L. 
(madder  
root) 
Hydroxyanthra-
quinones, 
lucidin
Traditional medicine  
and dye. Ayurveda,  
and in Europe for  
kidney stones.
Rodents
in vitro
 liver and kidney malign tumors and 
DNA adducts, in male and female rats. 
Mutagenic in S. thyphimurium TA 100 
and TA 98 assay, V79 HGPRT assay, 
malignant transformation assay with 
C3H/M2 cells.
Blömeke et al., 1992, 
Westendorf et al.,  
1988; 1998, Yasui and  
Takeda, 1983.
Senna  
alata L.  
(Roxb)
Sennosides
Traditional medicine 
(Africa, Nigeria, Ghana, 
Guinea).
Rodents
in vitro
Mutagenic to S. thyphimurium TA98 
and TA 1537 with S-9.
Hong and Lyu, 2011.
Mixture 
of plants 
called Imbiza 
ephuzwato, 
Stameta¥
BODicare®
(?)
Tradional medicine multi-
purpose remedies and 
tonics (South Africa,  
The Zulu).
in vitro
Plant mixtures were mutagenic in S. 
thyphimurium TA 98 assay  
with S9 activation.
Ndhlala et al., 2010; 2011.
 Areca catechu (betel quid) also contains carcinogenic arecatannins.
Chart 1
Examples of traditional herbal medicines and/or their constituents with suspected carcinogenic effects.
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Plant species Constituent Kinetic interactions Clinical/Experimental findings References
Gingko biloba L.
flavonoids; terpene 
lactones  
(ginkgolides)
CYP3A4 (ind/inh), 
2C9, 2C19 (ind, 
HD); P-glycoprotein 
(ABCD1) (ind/inh).
n CYP2C19-hydroxilation of omeprazole,  
p plasma levels of omeprazole,  
p plasma levels and AUC of midazolam.
Chen et al., 2011;  
Hermann and von Richter, 
2012; Li et al., 2013.
Allium sativum L.  
(garlic)
alliin, allicin; 
flavonoids; 
isoflavonoids; 
terpenes
CYP2E1 (inh), pgP 
(ABCD1) (ind).
p AUC saquinavir. Gurley et al., 2002; 2005; 
Hajda et al., 2010.
Silybum marianum (L.) 
Gaertn.  
(milk thistle)
flavolignans, 
silymarin  
mixture
CYP3A4 and 2C9 
(inh), UGT1A1, 1A6, 
1A9, 2B7, 2B15.
p clearance: metronidazole and 
hydroxymetranidazole,  
n AUC of losartan.
Chen et al., 2011;  
Sridar et al., 2004.
Hypericum perforatum L. 
(St. John’s wort)
hypericin, 
hyperforin; 
favonoids; 
biflavonois
CYP3A4 and 2B6 
(ind / inh);  
CYPC19, UGT,  
GST, PgP  
(ABCD1) (ind).
p (ind) / n (inh) AUC: cyclosporine, tracolimus, 
imatinib, warfarin, digoxin, verapamil, nifedipine, 
finasteride, glicazide, theophylline, bupropion, 
amitriptyline, midazolam, atorvastatin, nevirapine, 
indinavir, methadone, omeprazole and others.
Chen et al., 2011;  
Li et al., 2013.
Citrus × paradisi Macfad.
(grape fruit juice)
Narigin (?) CYP3A4.
n AUC: dihydropyridines, terfenadine, saquinavir, 
cyclosporin, midazolam, triazolam, verapamil, 
lovastatin, cisapride and astemizole.
Bailey et al., 1998;  
Fuhr, 1998.
ind: enzyme induction (previous and or repeated administration); inh: enzyme inhibition (concomitant administration); HD: high doses; UGT: 
UDP-glucuronosyltransferases.
Chart 3
Pharmacokinetic interactions of herbal medicines and edible plants with conventional drugs.
Plant species Constituent Clinical/Experimental observations References
Larrea tridentata (DC.)  
Coville 
 (chaparral) 
nordihydro- 
guiarectic  
acid (?)
Leaves from a desert shrub which are traditionally used in  
Southwestern USA and Mexico for a variety of therapeuthic  
indications. Reports of hepatocellular injury and cholestatic  
hepatitis (jaundice, marked increase of ALT) after weeks of use  
symptoms generally resolved on ingestion cessation.
Sheikh et al., 1997.
Teucrium chamaedrys L., 
T. polium L., T. viscidum 
Blume, T. capitatum L., 
(germander)
furano-
diterpenoids
Europe and Middle East, blossons traditionally used to treat  
various conditions. Reports of hyperbilirubinemia, anorexia,  
nausea, marked elevations of ALT, after 2 months of use.  
Some cases, fulminant hepatitis requiring liver transplantation.
Larrey et al., 1992;  
Lekehal et al., 1996;  
Mimidis et al., 2009.
Piper methysticum G. 
Forst.  
(kava kava)
piper- 
methysticin (?)
South Pacific traditional use as a recreational and cerimonial drink. 
Reports of hepatocellular and cholestasis pattern of liver injury, 
highly variable cummulative doses and latency periods. some 
underwent liver transplantation. Idiosyncratic DILI.
Moulds and Malani, 2003;  
Olsen et al., 2011;  
Teschke, 2010.
Symphytum officinale 
L. (comfrey) Senecio 
sp., Heliotropium sp., 
Crotalaria sp.
pyrrolizidine 
alkaloids
Europe, Asia, South Africa, USA, Jamaica, worldwide traditional 
medicine. venous occlusive disease, abdominal pain, ascites, slight 
jaundice and hepatomegaly (similar to Budd-Chiari Syndrome).
Steenkamp et al., 2000; 
Zuckerman et al., 2002.
Atractylis gummifera L.
atractylosides, 
gummiferin
Mediterranean region use as antipyretic, emetic, diuretic, chewing 
gum. Acute hepatitis, nephrotoxicity, hepatorenal failure.
Daniele et al., 2005;  
Larrey, 1997.
Callilepsis laureola 
DC.(Impila) 
atractylosides
South Africa use in Zulu traditional medicine. Acute liver and  
kidney injury, abdominal pain, diarrhea, vomiting, high mortality. 
Popat et al., 2001; 2002.
Chelidonium majus L. celandine
Europe and temperate regions of Asia. Used to treat dyspepsia,  
biliary colic, cholelithiasis. Several case reports describing acute  
liver injury, moderate elevations of ALT, marked cholestasis, 
recovery after herbal medicine discontinuation.
Benninger et al., 1999; Seeff, 
2007.
Mixture of plants  
(Herbalife® products)
(?)
Widespread use as food supplement. Case series of  
fulminant liver failure, hepatocellular damage,  
veno-occlusive disease and cholestasis.+ 
Bunchorntavakul and Reddy 
2013; Manso et al., 2011; 
Schoepfer et al., 2007; Teschke 
et al., 2012.
+The comment of Herbalife® manufacturers on the report of DILI cases possibly associated to their product is found in a letter by Appelhans et al. 
(2013) and authors’ reply in Reddy and Bunchorntavakul (2013).
Chart 2
Traditional herbal medicines associated with human liver injury.
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analysis, recent studies have also identified deficiencies in 
the quality of herbal medicines trial reports. In most cases, 
reports on clinical trials of herbal drugs do not contain all of 
the information recommended by CONSORT (Consolidated 
Standards of Reporting Trials) guidelines (Claraco et al., 2003; 
Bian et al, 2006; Gagnier et al., 2006). The scarcity of clinical 
trials with high methodological quality is an insurmounchart 
obstacle for the production of good systematic reviews of 
clinical data on the safety and efficacy of herbal medicines. 
Methodological drawbacks and poor quality of reports in 
clinical trials may explain why the conclusions of published 
systematic reviews on the safety and efficacy of herbal drugs 
are generally elusive or contradictory (Linde and Willich, 2003; 
Davidson et al., 2013; Liu et al, 2013). These deficiencies are 
also the reason why most Cochrane reviews, a gold standard 
reference for evidence-based therapeutic interventions of 
herbal drugs, conclude that no well-designed, randomized, 
placebo-controlled trial with objective outcome measures has 
been conducted, and thus, there is no evidence to support 
effectiveness and safety for the proposed clinical indication 
(Linde et al., 2006; Myiasaka et al., 2006; 2007, Dat et al., 2012; 
Leach and Moore, 2012; Pitler and Ernest, 2012; Wider et al., 
2013).
Some authors, however, rank traditional use, proven by 
sound historical research, one level above expert’s opinion 
based on medical rationalism rather than on empirical 
evidence arising from clinical trials. Along this line, John K. 
Crellin (2001) advanced the notion of “social validation”, and 
based on it, the author suggested that popular beliefs and 
“therapeutic wisdom” formed during successive generations 
are not to be neglected as a valid source of evidence. The 
recognition that traditional use is indeed a valid source of 
evidence, however, does not imply that clinical trials are in 
one way or another unnecessary to support the rational use 
of herbal medicines.
Commenting on the sources of evidence for efficacy, 
Verpoorte and other authors (Verpoorte et al., 2005; Carmona 
and Pereira, 2013) suggested that EBM approaches tend to 
overlook a crucial difference between herbal and conventional 
medicines. According to them, herbal medicines developed 
by communities and traditional healers suit a “holistic” 
view of health and the disease process, while conventional 
drug therapy reflects a reductionist approach focusing on a 
known therapeutic target (Verpoorte et al., 2005). A single 
target approach used to investigate efficacy of conventional 
drugs would miss the outcome of synergic interactions of 
herbal drugs on multiple targets. Similarly, some researchers 
argue that complex mixtures (phytocomplexes) found in 
herbal medicines would exhibit therapeutic effects greater 
than those conveyed by an isolated compound, and thus, the 
complex composition would be in fact an advantage of herbal 
drugs. The foregoing instigating hypothesis on the mode of 
action of “herbal drug complex mixtures” deserves to be 
adequately tested; however, regardless of the mechanism 
by which herbal medicines exert their therapeutic actions, 
clinical studies remain necessary to demonstrate that their 
use is, in fact, effective and safe.
European and Brazilian regulatory agencies show some 
leniency regarding the proof of efficacy of herbal drugs and 
alternative therapies presumed to be safe. However, any 
leniency regarding proof of safety of therapeutic interventions 
of unproven efficacy seems inadmissible. If clinical superiority 
over a placebo is small or unproven, safety criteria should 
be more stringent because, in this case, even low risks of 
adverse events, and those of minor severity, turn the risk-to-
benefit ratio unfavorable. As mentioned previously, except 
for short-term and overtly manifested toxic effects, long-
standing traditional use does not ensure that a medicinal 
plant is safe. This holds particularly true for long-term effects, 
such as cancer and morbidities not easily detected. There 
are indications that a number of traditionally used herbal 
medicines and/or their constituents are carcinogens and/
or cause liver injury. Moreover, safety concerns also arise 
from possible kinetic interactions between herbal products 
and conventional drugs. These interactions can bring 
about adverse events that are not fully disclosed under the 
conditions of traditional use.
The safe use of medicines requires both a pre-clinical 
and clinical evaluation of toxicity and post-marketing 
pharmacovigilance. Post-marketing pharmacovigilance is 
essential to bring problems of effectiveness and rare adverse 
effects (e.g., idiosyncratic DILI and immuno-allergic reactions), 
the occurrence of which is not anticipated by experimental and 
clinical studies. In contrast to newly developed conventional 
drugs, the safety assessment of traditionally used herbal 
medicines can also take into account a pre-marketing 
spontaneous report of ADR. Nonetheless, as mentioned 
previously, pharmacovigilance of herbal products faces a 
number of additional difficulties and needs to be considerably 
improved.
Finally, it should be emphasized that even though 
traditional use does not ensure the safety and effectiveness 
of herbal medicines, it is a useful guide for identification of 
new pharmacologically active substances in plants. A reverse 
pharmacology/toxicology or “bedside-to-bench” approach 
starting with a rigorous collection of clinical data in field 
surveys, as suggested by Graz (2013), may also be a fruitful 
strategy to improve knowledge on the safety of traditionally 
used herbal medicines.
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